DK1361439T3 - Screening for peptider, der hæmmer PP1c-binding til Bcl-2, Bcl-xl- og Bcl-w-proteiner - Google Patents

Screening for peptider, der hæmmer PP1c-binding til Bcl-2, Bcl-xl- og Bcl-w-proteiner

Info

Publication number
DK1361439T3
DK1361439T3 DK02291170T DK02291170T DK1361439T3 DK 1361439 T3 DK1361439 T3 DK 1361439T3 DK 02291170 T DK02291170 T DK 02291170T DK 02291170 T DK02291170 T DK 02291170T DK 1361439 T3 DK1361439 T3 DK 1361439T3
Authority
DK
Denmark
Prior art keywords
bcl
proteins
inhibit
peptides
screening
Prior art date
Application number
DK02291170T
Other languages
Danish (da)
English (en)
Inventor
Xavier Cayla
Angelita Rebollo
Alphonse Garcia
Original Assignee
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut filed Critical Pasteur Institut
Application granted granted Critical
Publication of DK1361439T3 publication Critical patent/DK1361439T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
DK02291170T 2002-05-07 2002-05-07 Screening for peptider, der hæmmer PP1c-binding til Bcl-2, Bcl-xl- og Bcl-w-proteiner DK1361439T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02291170A EP1361439B1 (en) 2002-05-07 2002-05-07 Screening for peptides inhibiting PP1c binding to Bcl-2, BCL-Xl and BCL-W proteins

Publications (1)

Publication Number Publication Date
DK1361439T3 true DK1361439T3 (da) 2007-03-26

Family

ID=29225746

Family Applications (3)

Application Number Title Priority Date Filing Date
DK02291170T DK1361439T3 (da) 2002-05-07 2002-05-07 Screening for peptider, der hæmmer PP1c-binding til Bcl-2, Bcl-xl- og Bcl-w-proteiner
DK06023212T DK1788394T3 (da) 2002-05-07 2002-05-07 Screening for peptider, der hæmmer PP1c binding til Bcl-2, BCL-Xl og BCL-W proteiner
DK03749894T DK1502116T3 (da) 2002-05-07 2003-05-06 Screening for peptider, der inhiberer PP1C-binding til BCL-2-, BCL-XL- og BCL-W-proteiner

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK06023212T DK1788394T3 (da) 2002-05-07 2002-05-07 Screening for peptider, der hæmmer PP1c binding til Bcl-2, BCL-Xl og BCL-W proteiner
DK03749894T DK1502116T3 (da) 2002-05-07 2003-05-06 Screening for peptider, der inhiberer PP1C-binding til BCL-2-, BCL-XL- og BCL-W-proteiner

Country Status (13)

Country Link
US (2) US7741288B2 (sl)
EP (4) EP1788394B1 (sl)
AT (4) ATE434186T1 (sl)
AU (1) AU2003242569A1 (sl)
CA (1) CA2484211A1 (sl)
CY (2) CY1107367T1 (sl)
DE (4) DE60232691D1 (sl)
DK (3) DK1361439T3 (sl)
ES (3) ES2327773T3 (sl)
HK (3) HK1062198A1 (sl)
PT (3) PT1788394E (sl)
SI (1) SI1502116T1 (sl)
WO (1) WO2003096022A2 (sl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT413945B (de) 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit
US8455628B2 (en) * 2007-05-02 2013-06-04 Intrexon Corporation PP1 ligands
EP2348038A1 (de) * 2010-01-22 2011-07-27 Philipps-Universität Marburg Verfahren zur Bestimmung der Aktivität der Transglutaminase Faktor XIIIa
WO2015171591A1 (en) * 2014-05-05 2015-11-12 Board Of Trustees Of The University Of Arkansas COMPOSITIONS AND METHODS FOR INHIBITING ANTIAPOPTOTIC Bcl-2 PROTEINS AS ANTI-AGING AGENTS
WO2015171957A1 (en) * 2014-05-07 2015-11-12 DOUGLASS, Alyse, N. Plasmodium liver-stage inhibitors and related methods
WO2016014625A1 (en) 2014-07-22 2016-01-28 Board Of Trustees Of The University Of Arkansas Compositions and methods for selectively depleting senescent cells
JP6936498B2 (ja) 2016-04-21 2021-09-15 バイオベンチャーズ・リミテッド・ライアビリティ・カンパニーＢｉｏＶｅｎｔｕｒｅｓ， ＬＬＣ 抗アポトーシス性Ｂｃｌ−２ファミリータンパク質の分解を誘導する化合物及びその使用
CN108218962B (zh) * 2017-12-29 2021-06-08 广西中医药大学 小分子多肽及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
EP0247091B1 (en) 1985-11-01 1993-09-29 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
ATE149570T1 (de) 1992-08-17 1997-03-15 Genentech Inc Bispezifische immunoadhesine
WO1997037224A1 (en) * 1996-03-30 1997-10-09 Medical Research Council Protein phosphatase-1 catalytic subunit interactions
JP4544715B2 (ja) * 1999-08-17 2010-09-15 成男 太田 ラットｂｃｌ−ｘ遺伝子の改変型ｃＤＮＡと改変型タンパク質
US7521548B2 (en) * 2001-02-07 2009-04-21 Burnham Institute For Medical Research Apoptosis modulator Bcl-B and methods for making and using same
WO2002074931A2 (en) * 2001-03-20 2002-09-26 University Of Chicago Inhibitors and disassemblers of fibrillogenesis
US9002545B2 (en) 2011-01-07 2015-04-07 Wabtec Holding Corp. Data improvement system and method

Also Published As

Publication number Publication date
ES2300603T3 (es) 2008-06-16
CY1107367T1 (el) 2012-12-19
DK1502116T3 (da) 2008-05-13
EP1361439B1 (en) 2006-11-15
HK1119249A1 (en) 2009-02-27
EP1788394A1 (en) 2007-05-23
CY1109383T1 (el) 2014-07-02
PT1788394E (pt) 2009-08-13
WO2003096022A8 (en) 2004-06-03
DK1788394T3 (da) 2009-10-19
US7741288B2 (en) 2010-06-22
ATE434186T1 (de) 2009-07-15
ATE472104T1 (de) 2010-07-15
US20110028387A1 (en) 2011-02-03
WO2003096022A2 (en) 2003-11-20
DE60232691D1 (de) 2009-07-30
DE60318427D1 (de) 2008-02-14
EP1502116A2 (en) 2005-02-02
ATE382864T1 (de) 2008-01-15
DE60216048T2 (de) 2007-05-31
EP1933150A1 (en) 2008-06-18
ATE345504T1 (de) 2006-12-15
CA2484211A1 (en) 2003-11-20
US20050244844A1 (en) 2005-11-03
DE60216048D1 (de) 2006-12-28
ES2327773T3 (es) 2009-11-03
PT1361439E (pt) 2007-02-28
EP1502116B1 (en) 2008-01-02
DE60318427T2 (de) 2008-12-18
EP1933150B1 (en) 2010-06-23
EP1788394B1 (en) 2009-06-17
PT1502116E (pt) 2008-04-15
AU2003242569A8 (en) 2003-11-11
AU2003242569A1 (en) 2003-11-11
ES2276895T3 (es) 2007-07-01
HK1062198A1 (en) 2004-10-21
DE60333138D1 (de) 2010-08-05
SI1502116T1 (sl) 2008-06-30
WO2003096022A3 (en) 2004-04-01
HK1078337A1 (en) 2006-03-10
EP1361439A1 (en) 2003-11-12

Similar Documents

Publication Publication Date Title
CY1109383T1 (el) Σαρωση για πεπτιδια που αναστελλουν την προσδεση της pp1c, στις πρωτεϊνες bcl-2, bcl-xl και bcl-w
WO2008043822A3 (en) Amino acid sequences that bind to a desired molecule in a conditional manner
BRPI0616712B8 (pt) método para amidar polipeptídeos com terminais c de aminoácido básicos por meio de endoproteases específicas
UA103154C2 (uk) Hla-a*1101-обмежений пептид wt1 і фармацевтична композиція, яка містить його
ATE368688T1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
Schneider et al. Posttranslational modifications of trichomonad tubulins; identification of multiple glutamylation sites
ATE212065T1 (de) Nukleinsäuremoleküle mit der fähigkeit zur unterscheidung von prpc und prpsc-prionprotein- isoformen und verfahren zu deren herstellung
SE9503679D0 (sv) Antioxidants
ATE362487T1 (de) N-substituierte l-aminosäuren enthaltende peptide,zur prävention der beta-strang assoziation
WO2005044845A3 (en) Protein binding miniature proteins
EA200601749A1 (ru) Коспептин, космедин и варианты их применения
WO2003010184A3 (en) A conserved xiap-interaction motif in caspase-9 and smac/diablo for mediating apoptosis
ATE405827T1 (de) Screening-verfahren
WO2005040802A3 (en) Cylin binding peptides, and their use in drug screening assays
WO2003060067A3 (en) P85-alpha nucleic acids, polypeptides and related methods
ATE235509T1 (de) Peptide zur inhibition von hpv e7 proteinen
DE602004021922D1 (de) Induktion der blütenbildung
EP1455186A4 (en) SCREENING METHOD
WO2004013167A3 (en) Purified polypeptides from enterococcus faecalis
WO2004076473A3 (en) Androgen receptor interacting peptides
WO2002044373A3 (en) Adipocyte complement related protein zacrp12
CY1113998T1 (el) Πρωτεϊνες που δεσμευουν αλβουμινη ορου
EP1724347A3 (en) DNA & protein binding miniature proteins
CY1111301T1 (el) Πολυπεπτιδια που προερχονται απο προδρομο πεπτιδιο αμυλοειδους (αρρ) και οι χρησεις αυτων